Ligand licenses topiramate injection to CURx
This article was originally published in Scrip
Executive Summary
San Diego-based Ligand Pharmaceuticals has licensed its injection formulation of epilepsy drug topiramate to CURx Pharmaceuticals in a deal potentially worth over $21m.